Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus
Cross-sectional Multicenter Study Aimed at Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus
University Hospital, Toulouse
233 participants
Oct 8, 2022
OBSERVATIONAL
Conditions
Summary
This multicenter study aims to evaluate treatment adherence and satisfaction of patients with cutaneous lupus, influenced by perception of the disease, fear of side effects, cost of medications and the doctor-patient relationship. Adherence will be measured by a VAS of 80% or higher on the Medical Adherence Self-Report Inventory scale.
Eligibility
Inclusion Criteria4
- Patients with cutaneous lupus (pure cutaneous or subacute) diagnosed by a dermatologist and under local and/or systemic treatment for cutaneous lupus
- No opposition to participation
- Patient able to complete the questionnaires
- Adult patient
Exclusion Criteria4
- Systemic lupus with multiple visceral involvement
- Cognitive or psychiatric disorders preventing the smooth running of the study
- Pregnant woman
- Patient under guardianship/curatorship or safeguard of justice
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Responses to questionnaires: * Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) * Medical Adherence Self-Report Inventory (MASRI) * Morisky Medication Adherence Scale (MMAS4) * Visual analog scale (VAS) on the perception of disease control * Belief on Medicine Questionnaire (BMQ) * Care patient Feedback measure * Hospital Anxiety and Depression Scale (HAD) * Dermatology Life Quality Index (DLQI)
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06506214